Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
DTIL 
Precision BioSciences Inc (DTIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/19/2025: DTIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32.5
1 Year Target Price $32.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.17% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/19/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 108.08M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 4 | Beta 1.11 | 52 Weeks Range 3.61 - 8.82 | Updated Date 12/20/2025 |
52 Weeks Range 3.61 - 8.82 | Updated Date 12/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -158976.92% |
Management Effectiveness
Return on Assets (TTM) -45.34% | Return on Equity (TTM) -205.16% |
Valuation
Trailing PE - | Forward PE 11.78 | Enterprise Value 92340161 | Price to Sales(TTM) 154.85 |
Enterprise Value 92340161 | Price to Sales(TTM) 154.85 | ||
Enterprise Value to Revenue 132.29 | Enterprise Value to EBITDA -0.27 | Shares Outstanding 24071751 | Shares Floating 12564881 |
Shares Outstanding 24071751 | Shares Floating 12564881 | ||
Percent Insiders 5.87 | Percent Institutions 23.64 |
Upturn AI SWOT
Precision BioSciences Inc
Company Overview
History and Background
Precision BioSciences Inc. was founded in 2006 with the goal of developing a revolutionary genome editing platform. It emerged from the pioneering work of its founders in the field of engineered nucleases. The company's journey has been marked by the development of its proprietary ARCUSu00ae genome editing platform, a key differentiator in the gene therapy and agricultural biotechnology sectors. Significant milestones include building a robust pipeline of therapeutic candidates and establishing partnerships with major pharmaceutical and agricultural companies.
Core Business Areas
- Gene Therapy: Precision BioSciences focuses on developing in vivo and ex vivo gene therapies for a range of serious diseases, leveraging its ARCUSu00ae genome editing technology to precisely modify DNA. The company aims to address unmet medical needs in areas such as oncology, autoimmune disorders, and rare genetic diseases.
- Ag-Biotransformation: Precision BioSciences also applies its genome editing technology to the agricultural sector, aiming to develop crops with improved traits such as enhanced nutritional value, increased yield, and resistance to pests and diseases. This segment focuses on creating more sustainable and efficient food production systems.
Leadership and Structure
Precision BioSciences is led by a management team with extensive experience in biotechnology, gene editing, and pharmaceutical development. The company operates under a typical corporate structure with departments dedicated to research and development, clinical operations, manufacturing, commercial, and corporate functions. Specific details on the current leadership team can be found in their SEC filings and investor relations materials.
Top Products and Market Share
Key Offerings
- Description: The core technology platform that enables precise DNA modification. This platform is the foundation for all of Precision BioSciences' therapeutic and agricultural applications. Market share data for a platform technology is not directly applicable. Competitors include other gene editing technologies such as CRISPR-Cas9 (e.g., Editas Medicine, Intellia Therapeutics, Beam Therapeutics) and TALENs (e.g., Cellectis).
- Product Name 1: ARCUSu00ae Genome Editing Platform
- Description: A lead in vivo gene therapy candidate designed to elicit a potent anti-tumor immune response in patients with head and neck squamous cell carcinoma. Market share is not yet applicable as it is an investigational product. Competitors in head and neck cancer therapies include traditional chemotherapy, immunotherapy (e.g., Merck's Keytruda, Bristol Myers Squibb's Opdivo), and other novel therapeutic approaches.
- Product Name 2: PDS0101 (Candidate)
- Description: A preclinical ex vivo gene therapy candidate for the treatment of certain rare genetic disorders. Market share is not yet applicable. Competitors depend on the specific rare genetic disorder, which may include other gene therapy developers and companies offering enzyme replacement therapies or other treatments.
- Product Name 3: PB-104 (Candidate)
Market Dynamics
Industry Overview
Precision BioSciences operates within the rapidly evolving fields of gene therapy and biotechnology. The gene therapy market is characterized by high R&D investment, significant scientific innovation, and a growing pipeline of therapeutic candidates for previously untreatable diseases. The agricultural biotechnology sector is focused on sustainable solutions, improved crop yields, and enhanced nutritional content, driven by global food security concerns and environmental sustainability goals.
Positioning
Precision BioSciences is positioned as an innovator in genome editing technology with its proprietary ARCUSu00ae platform, which offers distinct advantages in terms of precision and safety compared to some other gene editing systems. The company's strategy involves both internal pipeline development and strategic partnerships to leverage its technology across multiple therapeutic areas and agricultural applications.
Total Addressable Market (TAM)
The TAM for gene therapy is projected to reach tens of billions of dollars, driven by the potential to treat a wide range of genetic and acquired diseases. The agricultural biotechnology market is also substantial, with ongoing demand for crop improvement solutions. Precision BioSciences is positioned to capture a share of this TAM by developing and commercializing its gene editing-based products and technologies.
Upturn SWOT Analysis
Strengths
- Proprietary ARCUSu00ae genome editing platform with potential advantages in precision and safety.
- Experienced scientific and management team.
- Robust pipeline of therapeutic candidates in preclinical and clinical development.
- Strategic partnerships with established players in the pharmaceutical and agricultural industries.
Weaknesses
- Relatively early stage of product development, with limited approved products.
- High R&D costs and long development timelines inherent to gene therapy and biotech.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Competition from well-established companies and other innovative gene editing platforms.
Opportunities
- Advancements in gene therapy and genome editing technologies.
- Growing demand for novel treatments for rare and complex diseases.
- Expansion of applications in agricultural biotechnology for sustainable food production.
- Potential for new strategic partnerships and collaborations.
Threats
- Clinical trial failures or adverse events.
- Regulatory hurdles and delays in obtaining approvals.
- Intensifying competition from other gene editing companies.
- Changes in reimbursement policies for advanced therapies.
- Patent challenges and intellectual property disputes.
Competitors and Market Share
Key Competitors
- CRISPR Therapeutics (CRSP)
- Intellia Therapeutics (NTLA)
- Editas Medicine (EDIT)
- Beam Therapeutics (BEAM)
Competitive Landscape
Precision BioSciences differentiates itself through its ARCUSu00ae genome editing platform, which it claims offers superior precision and a potentially better safety profile than other gene editing tools. However, it faces strong competition from companies with more advanced clinical pipelines or larger market capitalization. Success will depend on demonstrating clear clinical advantages and navigating the complex regulatory and commercial landscape.
Growth Trajectory and Initiatives
Historical Growth: Precision BioSciences has demonstrated growth in its research capabilities and pipeline advancement over its history. This includes the progression of its gene therapy candidates into clinical trials and the expansion of its technological platform's applications. Revenue growth, if any, has been tied to partnership milestones rather than product sales.
Future Projections: Future growth is projected to be driven by the successful development and commercialization of its gene therapy candidates, as well as potential advancements and licensing in its agricultural biotechnology segment. Analyst estimates would need to be consulted for specific quantitative projections, but the overall trajectory is dependent on clinical success and market adoption.
Recent Initiatives: Recent initiatives likely include advancing its lead gene therapy candidates through clinical trials, forging new strategic partnerships, and potentially expanding its research into new therapeutic areas or disease indications. The company also focuses on further refining and leveraging its ARCUSu00ae platform.
Summary
Precision BioSciences Inc. is a biotechnology company focused on developing innovative gene therapies and agricultural solutions using its proprietary ARCUSu00ae genome editing platform. Its strengths lie in its unique technology and experienced team, while its weaknesses include its early-stage development and reliance on future clinical success. Opportunities exist in the growing gene therapy market and sustainable agriculture, but the company faces significant threats from competition, regulatory challenges, and the inherent risks of drug development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Websites
- Biotechnology Industry Reports
- Financial News and Analysis Websites
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Investing in biotechnology stocks involves significant risks. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share percentages are estimates and subject to change. Financial data is based on publicly available information and may not be exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precision BioSciences Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2019-03-28 | President, CEO & Director Mr. Michael Amoroso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://precisionbiosciences.com |
Full time employees 67 | Website https://precisionbiosciences.com | ||
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.